SMARCA4 and lung carcinoma: Recent studies have found that treatment with immune checkpoint inhibitors is associated with improved outcomes in patients with SMARCA4 mutated, suggesting that SMARCA4 mutated lung cancer may be more sensitive to immunotherapy.